Conditions: Hepatocellular Carcinoma Hepatoma
Keywords: primary liver cancer sorafenib Nexavar doxorubicin drug eluting beads transarterial chemoembolization
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 50
Healthy volunteers: no

Brief summary:
This study will combine two therapies to treat patients with unresectable hepatocellular carcinoma; sorafenib, and drug eluting beads delivered intra-arterially. The purpose of the study is to establish the safety and the effectiveness of the combination therapy. The investigators hypothesize that the combination of the two therapies will not result in greater toxicities to patients than that expected for either therapy given alone.

Detailed description:

Arms:
arm 1: single arm

Interventions: intervention 1: sorafenib intervention 2: LC Bead-TACE
Intervention descriptions: intervention 1: sorafenib: given 400 mg twice per day for as long as it is beneficial intervention 2: LC Beads loaded with doxorubicin

Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period

Protocol document: